N-[6-[5-(tert-butylsulfamoyl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]acetamide | 1010120-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[6-[5-(tert-butylsulfamoyl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]acetamide
• CAS: 1010120-40-7
• 化学式: C₁₇H₂₀N₆O₃S
• 分子量: 388.45
• InChiKey: UFUYIYALRJTKDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[6-[5-(tert-butylsulfamoyl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]acetamide 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 生成 CZC 19945
  参考文献：
  名称：

  SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors

  摘要：

  Herein we describe the SAR of a novel series of 6-aryl-2-amino-triazolopyridines as potent and selective PI3K gamma inhibitors. The 6-aryl-triazolopyridine core was identified by chemoproteomic screening of a kinase focused library. Rapid chemical expansion around a bi-functional core identified the key features required for PI3K gamma activity and selectivity. The series was optimized to afford 43 (CZC19945), a potent PI3K gamma inhibitor with high oral bioavailability and selectivity over PI3K alpha and PI3K delta. Modification to the core afforded 53 (CZC24832) which showed increased selectivity over the entire kinome in particular over PI3K beta. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.049

文献信息

• TRIAZOLE DERIVATIVES AS KINASE INHIBITORS
  申请人：Wilson Francis

  公开号：US20100227800A1

  公开（公告）日：2010-09-09

  The invention relates to compounds of formula (I); wherein X and R 1 to R 5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.

  本发明涉及式(I)的化合物；其中X和R1至R5的含义如所述及权利要求中所述。所述化合物可用作蛋白激酶抑制剂，特别是Itk或PI3K的抑制剂，用于治疗或预防免疫、炎症或过敏性疾病。本发明还涉及包括所述化合物的制药组合物，以及制备这些化合物的方法以及作为药物的生产和使用。
• US8883820B2
  申请人：——

  公开号：US8883820B2

  公开（公告）日：2014-11-11
• [EN] TRIAZOLE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE TRIAZOLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：CELLZOME UK LTD

  公开号：WO2008025821A1

  公开（公告）日：2008-03-06

  [EN] The invention relates to compounds of formula (I); wherein X and R¹ to R⁵ have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
  [FR] L'invention concerne des composés de formule (I), dans laquelle X et R¹ à R⁵ ont les significations données dans la description et dans les revendications. Lesdits composés sont utiles en tant qu'inhibiteurs de protéine kinase, notamment en tant qu'inhibiteurs de Itk ou PI3K, pour le traitement ou la prophylaxie de troubles immunologiques, inflammatoires ou allergiques. L'invention concerne également des compositions pharmaceutiques comprenant lesdits composés, la préparation de tels composés, ainsi que leur production et leur utilisation en tant que médicaments.
• SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors
  作者：Kathryn Bell、Mihiro Sunose、Katie Ellard、Andrew Cansfield、Jess Taylor、Warren Miller、Nigel Ramsden、Giovanna Bergamini、Gitte Neubauer

  DOI：10.1016/j.bmcl.2012.06.049

  日期：2012.8

  Herein we describe the SAR of a novel series of 6-aryl-2-amino-triazolopyridines as potent and selective PI3K gamma inhibitors. The 6-aryl-triazolopyridine core was identified by chemoproteomic screening of a kinase focused library. Rapid chemical expansion around a bi-functional core identified the key features required for PI3K gamma activity and selectivity. The series was optimized to afford 43 (CZC19945), a potent PI3K gamma inhibitor with high oral bioavailability and selectivity over PI3K alpha and PI3K delta. Modification to the core afforded 53 (CZC24832) which showed increased selectivity over the entire kinome in particular over PI3K beta. (c) 2012 Elsevier Ltd. All rights reserved.